?? Nvidia stock jumps on report CEO Jensen Huang is done selling shares after $713 million windfall
The articles and information in this newsletter are a summary of yesterday’s trading and related news. They are presented for informational purposes only. Nothing in the newsletter should be taken as investment or trading advice.
S&P 500 5,732.93 +14.36 (+0.25%)
Dow Jones 42,208.22 +83.57 (+0.20%)
NASDAQ 18,074.52 +100.25 (+0.56%)
Market close: September 24, 2024
Breaking News
Nvidia stock jumps on report CEO Jensen Huang is done selling shares after $713 million windfall ?? Nvidia stock closed 4% higher on a report that CEO Jensen Huang is done selling shares. Huang raked in $713 million in total proceeds from the sales. He remains Nvidia's biggest shareholder. Yahoo Finance reports.
Image source: Wikimedia Commons
EdgeUp
?? VWGenius: Google, Volkswagen partner on smartphone AI assistant. Reuters reports.
?? AIInside: Intel launches new AI chips as takeover rumors swirl. Yahoo Finance reports.
?? ParamountCuts: Paramount Global begins second phase of layoffs in US. Reuters reports.
?? GitSecure: Microsoft’s GitHub gives clients option to keep sensitive code in EU only, in data sovereignty push. CNBC reports.
?? VisaBlock: Visa falls on report of US DoJ lawsuit alleging debit-card monopoly. Reuters reports.
?? FlightGuard: FAA says Boeing safety culture reforms may take years. Yahoo Finance reports.
Top 5 Movers in Early Pre-Market
(All pricing and percent gains are based on Early Pre-Market from 4:00 AM to 7:00 AM Eastern Time) Benzinga reports.
1. $ATCH: AtlasClear Holdings
Total gain: +54.72%
2. $MSGM: Motorsport Games
Total gain: +31.81%
3. $ELYM: Eliem Therapeutics
Total gain: +21.81%
4. $VSME: VS Media Holdings
Total gain: +23.57%
5. $TOYO: Toyo Co
Total gain: +16.6%
A Question About Risk
Bob Iaccino is a chief market strategist and co-founder of Path Trading Partners. He joins us live every Thursday from 11am ET, as our Risk Management educator.
Why Should Traders Have a Plan for Their Target?
A target is a point where action is required, not optional. You must take action at your target, especially if it’s a measured move target, because you identified that target well before you entered the trade. Therefore, that target is important. The only time you can think clearly about a trade is before you're in it. A common mistake many traders make is when they see the price approaching the target, they think, "Oh, I'm almost at my target," and feel relieved. But then the day closes, and the next day the market opens lower—remember, this green area is the open, and the bottom of this candle is the open. Suddenly, you're thinking, "Oh my God, I'm going to make a fortune on this trade." In that excitement, you might prematurely exit your trade or fail to adjust your stop. You don't tighten your trailing stop, or you hesitate to reduce your stop loss because you don’t want to get stopped out. This behavior is careless and could cost you profits.
?? Read more
Refer a Friend & Earn Together
Did you know that it pays to invite your friends to TradeZero?When they fund a new account with us, you'll both receive $100 USD. T&Cs apply.
?? Learn More
Yesterday’s Biggest Movers
The closing price of the top three market percent gainers trading near or above $3 on September 24.
(All pricing and percent gains are based on regular market trading hours from 9:30am to 4:00pm Eastern Time)
1. $BNZI: Banzai International
Total gain: +92.62%
The company announced that it has entered into agreements with lenders and service providers to write off up to $5.6 million in outstanding liabilities and restructure an additional $19.2 million of its existing debt obligations. These actions improve the company’s overall financial position by amending certain credit terms and extending the maturity of specific debt facilities. Including the previously executed fee restructuring with Cantor Fitzgerald, this represents a total of $28.8 million in anticipated reduced and restructured liabilities. Benzinga reports.
2. $CAPR: Capricor Therapeutics
Total gain: +59.13%
The company announced its meetings with the U.S. Food and Drug Administration (FDA) and its intent to file a Biologics License Application (BLA) based on existing cardiac and natural history data for deramiocel, aimed at treating all patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy. Capricor plans to begin the BLA filing process in October 2024, seeking full approval for deramiocel in the treatment of DMD-cardiomyopathy, with the complete submission expected by the end of 2024. Benzinga reports.
3. $WVE: WAVE Life Sciences
Total gain: +43.45%
The company announced that it has commenced an underwritten public offering of $175 million in aggregate of its ordinary shares and, for certain investors, pre-funded warrants to purchase ordinary shares in lieu of ordinary shares. In connection with the offering, Wave intends to grant the underwriters a 30-day option to purchase additional ordinary shares, up to 15% of the total amount of ordinary shares and shares underlying the pre-funded warrants sold in the public offering, under the same terms and conditions. Benzinga reports.
Today’s Notable Earnings
(Estimate and Actual numbers represent Earnings Per Share in US Dollars)
MU Micron Technology
4Q 2024
Before Market Close Estimate: 1.130 Actual: N/A
JEF Jefferies Financial Group
3Q 2024
After Market Close Estimate: 0.770 Actual: N/A
FUL H.B. Fuller
3Q 2024
After Market Close Estimate: 1.230 Actual: N/A
Today’s Key Economic Dates
Time (ET) / Report / Period
10:00 am New home sales - August
4:00 pm Federal Reserve Governor Adriana Kugler speaks
Extra-Time
Visit Our Knowledge Corner
Parting Thoughts
“The true investor’s standard should be measured not by the day-to-day performance of his portfolio, but by the degree to which his portfolio meets his long-term financial objectives.” ― John C. Bogle
Sourced in: “The little book of common sense investing: The only way to guarantee your fair share of stock market returns”, by John C. Bogle, published in 2007